Terms: = Lymphoma AND BLM, MGC131620, 641, ENSG00000197299, MGC131618, RECQ2, RECQL2, RECQL3, MGC126616, BS
186 results:
1. Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia.
Pepeler MS; Tıglıoglu M; Dagdas S; Ozhamamcıoglu E; Han U; Albayrak A; Aydın MS; Korkmaz G; Pamukcuoğlu M; Ceran F; Albayrak M; Ozet G
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e161-e167. PubMed ID: 38342726
[TBL] [Abstract] [Full Text] [Related]
3. Elevated serum CA199 levels in patients suffering type 2 diabetes vs. various types of cancer.
Zhuang Y; Cai Q; Hu X; Huang H
BMC Endocr Disord; 2024 Jan; 24(1):9. PubMed ID: 38212751
[TBL] [Abstract] [Full Text] [Related]
4. Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Shimomura Y; Sawa K; Imai T; Ihara Y; Yoshida H; Shintani A
Cancer Sci; 2024 Mar; 115(3):926-936. PubMed ID: 38148717
[TBL] [Abstract] [Full Text] [Related]
5. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
Xu-Monette ZY; Li Y; Snyder T; Yu T; Lu T; Tzankov A; Visco C; Bhagat G; Qian W; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Wang Y; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Fan X; van Krieken JH; Piris MA; Winter JN; Au Q; Kirsch I; Zhang M; Shaughnessy J; Xu B; Young KH
Clin Cancer Res; 2023 Dec; 29(23):4808-4821. PubMed ID: 37728879
[TBL] [Abstract] [Full Text] [Related]
6. Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data.
Zakeri M; Li J; Sansgiry SS; Aparasu RR
J Manag Care Spec Pharm; 2023 May; 29(5):480-489. PubMed ID: 37121258
[No Abstract] [Full Text] [Related]
7. Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
Elsayad K; Weishaupt C; Moustakis C; Danzer MF; Müller EC; Rolf D; Stranzenbach R; Livingstone E; Booken N; Stadler R; Eich HT
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):164-170. PubMed ID: 36893819
[TBL] [Abstract] [Full Text] [Related]
8. Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia.
Nabil R; Abdellateif MS; Gamal H; Hassan NM; Badawy RH; Ghareeb M; El Ashry MS
Leuk Res; 2023 Mar; 126():107019. PubMed ID: 36657369
[TBL] [Abstract] [Full Text] [Related]
9. Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019.
van der Straten L; Levin MD; Dinnessen MAW; Visser O; Posthuma EFM; Doorduijn JK; Langerak AW; Kater AP; Dinmohamed AG
Blood Cancer J; 2023 Jan; 13(1):15. PubMed ID: 36635262
[TBL] [Abstract] [Full Text] [Related]
10. Characteristics and Outcomes of Alberta lymphoma Patients with a History of Immunosuppressive therapy for Autoimmune Conditions.
Kantharia K; Owen C; Stewart D; Yau P; Ghosh S; Dersch-Mills D
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):894-902. PubMed ID: 36031543
[TBL] [Abstract] [Full Text] [Related]
11. [Study on bone microstructure and pathology of type L2 and L3 osteonecrosis of the femoral head specimens classified by China-Japan Friendship Hospital classification based on "three-columns structure"].
Gao R; Xia X; Liu J; Yuan Z; Huan D; Shen J
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2022 Aug; 36(8):1003-1010. PubMed ID: 35979793
[TBL] [Abstract] [Full Text] [Related]
12. Comparison between filgrastim biosimilar and filgrastim original for the management of neutropenia after salvage chemotherapy for malignant lymphoma.
Shimano R; Yamamoto H; Nasu I; Kashiwamura Y; Yamamoto G; Uchida N; Taniguchi S; Hayashi M; Ito T
Int J Hematol; 2022 Dec; 116(6):856-862. PubMed ID: 35976562
[TBL] [Abstract] [Full Text] [Related]
13. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
Miller TP; Getz KD; Li Y; Demissei BG; Adamson PC; Alonzo TA; Burrows E; Cao L; Castellino SM; Daves MH; Fisher BT; Gerbing R; Grundmeier RW; Krause EM; Lee J; Lupo PJ; Rabin KR; Ramos M; Scheurer ME; Wilkes JJ; Winestone LE; Hawkins DS; Gramatges MM; Aplenc R
Lancet Haematol; 2022 Sep; 9(9):e678-e688. PubMed ID: 35870472
[TBL] [Abstract] [Full Text] [Related]
14. Genomic characterization of lymphomas in patients with inborn errors of immunity.
Ye X; Maglione PJ; Wehr C; Li X; Wang Y; Abolhassani H; Deripapa E; Liu D; Borte S; Du L; Wan H; Plötner A; Giannoula Y; Ko HB; Hou Y; Zhu S; Grossman JK; Sander B; Grimbacher B; Hammarström L; Fedorova A; Rosenzweig SD; Shcherbina A; Wu K; Warnatz K; Cunningham-Rundles C; Pan-Hammarström Q
Blood Adv; 2022 Sep; 6(18):5403-5414. PubMed ID: 35687490
[TBL] [Abstract] [Full Text] [Related]
15. Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution.
Richter-Pechańska P; Kunz JB; Rausch T; Erarslan-Uysal B; Bornhauser B; Frismantas V; Assenov Y; Zimmermann M; Happich M; von Knebel-Doeberitz C; von Neuhoff N; Köhler R; Stanulla M; Schrappe M; Cario G; Escherich G; Kirschner-Schwabe R; Eckert C; Avigad S; Pfister SM; Muckenthaler MU; Bourquin JP; Korbel JO; Kulozik AE
Leukemia; 2022 Jul; 36(7):1759-1768. PubMed ID: 35585141
[TBL] [Abstract] [Full Text] [Related]
16. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Sancho JM; Marín-Niebla A; Fernández S; Capote FJ; Cañigral C; Grande C; Donato E; Zeberio I; Puerta JM; Rivas A; Pérez-Ceballos E; Vale A; Martín García-Sancho A; Salar A; González-Barca E; Teruel A; Pastoriza C; Conde-Royo D; Sánchez-García J; Barrenetxea C; Arranz R; Hernández-Rivas JÁ; Ramírez MJ; Jiménez A; Rubio-Azpeitia E
Int J Hematol; 2022 Sep; 116(3):381-392. PubMed ID: 35551632
[TBL] [Abstract] [Full Text] [Related]
17. [Clinicopathological features of mature T/NK cell lymphoma with aberrant CD20 or CD79α expression].
Li DJ; Kang H; Zhang L; Xu ZG; Wang XY; Wang LF; Song XX; Kong LF
Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):413-418. PubMed ID: 35511636
[No Abstract] [Full Text] [Related]
18. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
Tanaka N; Mori S; Kiyotani K; Ota Y; Gotoh O; Kusumoto S; Nakano N; Suehiro Y; Ito A; Choi I; Ohtsuka E; Hidaka M; Nosaka K; Yoshimitsu M; Imaizumi Y; Iida S; Utsunomiya A; Noda T; Nishikawa H; Ueda R; Ishida T
Haematologica; 2022 Oct; 107(10):2418-2431. PubMed ID: 35417939
[TBL] [Abstract] [Full Text] [Related]
19. Retrospective analysis of the risk of neoplasia associated with unilateral maxillary sinus opacification on computed tomography.
Mughal Z; Daffu K; Adeoti R; Swaminathan R; Henney S
J Laryngol Otol; 2022 Dec; 136(12):1259-1264. PubMed ID: 35388775
[TBL] [Abstract] [Full Text] [Related]
20. Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.
Alrawashdh N; McBride A; Slack M; Persky D; Andritsos L; Abraham I
J Manag Care Spec Pharm; 2022 Apr; 28(4):390-400. PubMed ID: 35332792
[No Abstract] [Full Text] [Related]
[Next]
